References
Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842–7.
Battistella M, Rivet J, Bachelez H, Liote F. Lichen planus associated with etanercept. Br J Dermatol 2008; 158: 188–90.
Ramirez J, Hernandez MV, Galve J, Canete JD, Sanmarti R. Morphea associated with the use of adalimumab: a case report and review of the literature. Mod Rheumatol 2012; 22: 602–4.
Viguier M, Richette P, Bachelez H, Wendling D, Aubin F. Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders. Expert Rev Clin Immunol 2009; 5: 421–31.
Denadai R, Teixeira FV, Steinwurz F, Romiti R, Saad-Hossne R. Induction or exacerbation of psoriatic lesions during anti-TNF-alpha therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis 2013; 7: 517–24.
Wenzel J, Scheler M, Proelss J, Bieber T, Tuting T, Type T. I interferon-associated cytotoxic inflammation in lichen planus. J Cutan Pathol 2006; 33: 672–8.
Kim D, Peck A, Santer D, et al. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum 2008; 58: 2163–73.
Author information
Authors and Affiliations
Corresponding author
Additional information
These authors equally contributed as first authors.
About this article
Cite this article
Inoue-Nishimoto, T., Hanafusa, T., Igawa, K. et al. Possible association of anti-tumor necrosis factor-α antibody therapy with the development of scleroderma-like changes with lichen planus. Eur J Dermatol 25, 513–515 (2015). https://doi.org/10.1684/ejd.2015.2631
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2015.2631